Vanessa Nakate to Open Giving Black Conference 2026 With Climate Justice Keynote
2 weeks ago
United States Brenda Waning is a globally-recognized expert in pharmaceutical policy and access to medicines, currently serving as Chief of the Stop TB Global Drug Facility.
Brenda Waning obtained a Bachelor of Pharmacy degree and later joined the faculty as an Assistant Professor of Pharmacy Practice, where she taught courses and contributed to publications.
Brenda Waning is the Chief of the Global Drug Facility, a UN-hosted enterprise under the Stop TB Partnership, focusing on improving access to TB products through market-shaping and procurement.
Research was conducted in collaboration with these institutions, with financial support mentioned in a 2011 publication.
Brenda Waning is listed as an author for the textbook 'Pharmacoepidemiology: Principles and Practice', published by McGraw Hill Medical.
Brenda Waning holds a Bachelor of Pharmacy degree and has dedicated over 25 years to improving access to essential medicines. Her career began as an Assistant Professor of Pharmacy Practice at the Massachusetts College of Pharmacy and Allied Health Sciences in Boston, Massachusetts. During her tenure, she taught various courses and was also an author for ‘Pharmacoepidemiology: Principles and Practice’, a publication detailing the scientific study of the use and effects of medications in large populations. Her academic work involved collaboration with institutions like the Boston University School of Medicine and the Boston University School of Public Health.
Her experience spans academic, donor, and implementer roles, focusing on the critical intersection of pharmaceutical policy, market shaping, and equitable access to vital medications globally. This extensive background has positioned her as a leader in international public health, particularly in addressing challenges related to drug accessibility. Her professional journey includes significant work with the Stop TB Partnership, where she has been instrumental in market-shaping initiatives and procurement strategies for tuberculosis products.
Currently, as the Chief of the Stop TB Global Drug Facility, a UN-hosted enterprise, Brenda Waning’s mission is to enhance availability of TB products. This involves strategic market interventions, efficient procurement processes, development of innovative delivery systems, and providing technical assistance to improve global health outcomes. Her work directly contributes to global efforts in combating tuberculosis by ensuring that necessary treatments reach those in need, reflecting a sustained commitment to public health and pharmaceutical equity.
Curious about our offerings or have inquiries? We're eager to assist!
Just complete the form, and we'll respond promptly.
